Catabasis Pharmaceuticals to Host Virtual KOL Event on Edasalonexent and Duchenne Muscular Dystrophy
September 02 2020 - 8:00AM
Business Wire
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage
biopharmaceutical company, will be holding a virtual key opinion
leader (KOL) event to discuss edasalonexent, currently in Phase 3
clinical development for the treatment of Duchenne muscular
dystrophy (DMD), on Friday, September 11,.2020 at 9:00am ET.
The event will feature a discussion with Craig McDonald, M.D.,
Director, Neuromuscular Disease Clinics at UC Davis; Jill C. Milne,
Ph.D., Chief Executive Officer of Catabasis; Joanne M. Donovan,
M.D., Ph.D., Chief Medical Officer of Catabasis; Andrew A.
Komjathy, Chief Commercial Officer of Catabasis; and Mindy Cameron,
parent of a son affected by DMD.
The live webcast of the event can be accessed by using the
following link: https://www.webcaster4.com/Webcast/Page/2476/36576
or from the investors section of www.catabasis.com. An archived
replay will also be available for 30 days following the event.
About Edasalonexent (CAT-1004)
Edasalonexent (CAT-1004) is an investigational oral small
molecule designed to inhibit NF-kB that is being developed as a
potential foundational therapy for all patients affected by DMD,
regardless of their underlying mutation. In DMD the loss of
dystrophin leads to chronic activation of NF-kB, which is a key
driver of skeletal and cardiac muscle disease progression. The
ongoing global Phase 3 PolarisDMD trial is evaluating the efficacy
and safety of edasalonexent for registration purposes.
Edasalonexent is also being evaluated in the GalaxyDMD open-label
extension trial. In the MoveDMD Phase 2 trial and open-label
extension, the Company observed that edasalonexent preserved muscle
function and substantially slowed disease progression compared to
rates of change in a control period, and significantly improved
biomarkers of muscle health and inflammation. The FDA has granted
orphan drug, fast track, and rare pediatric disease designations
and the European Commission has granted orphan medicinal product
designation to edasalonexent for the treatment of DMD. For a
summary of clinical results, please visit www.catabasis.com.
About Catabasis
At Catabasis Pharmaceuticals, our mission is to bring hope and
life-changing therapies to patients and their families. Our lead
program is edasalonexent, an NF-kB inhibitor in Phase 3 development
for the treatment of Duchenne muscular dystrophy. For more
information on edasalonexent and our Phase 3 PolarisDMD trial,
please visit www.catabasis.com.
Forward Looking Statements
Any statements in this press release about future expectations,
plans and prospects for the Company, including statements about
edasalonexent potentially being a foundational therapy for DMD
patients, along with other statements containing the words
“believes,” “anticipates,” “plans,” “expects,” “may” and similar
expressions, constitute forward-looking statements within the
meaning of applicable securities regulations and laws. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including risks and uncertainties: inherent in the
initiation and completion of clinical trials and clinical
development; related to whether the results of earlier stage
clinical trials will be predictive of the results of later stage
trials; related to the regulatory review and approval process;
inherent in the commercialization of marketed products; related to
successfully managing the Company’s potential transformation into a
fully integrated company; related to competitive products,
including those already approved and those in development; related
to other matters that could affect the clinical development,
regulatory status, availability or commercial potential of
edasalonexent, as well as the risks and uncertainties discussed in
the “Risk Factors” section of the Company’s Quarterly Report on
Form 10-Q for the period ended June 30, 2020, which is on file with
the Securities and Exchange Commission, and in other filings that
the Company may make with the Securities and Exchange Commission in
the future. In addition, the forward-looking statements included in
this press release represent the Company’s views as of the date of
this press release. The Company anticipates that subsequent events
and developments will cause the Company’s views to change. However,
while the Company may elect to update these forward-looking
statements at some point in the future, the Company specifically
disclaims any obligation to do so. These forward-looking statements
should not be relied upon as representing the Company’s views as of
any date subsequent to the date of this release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200902005025/en/
Catabasis Investor and Media Andrea
Matthews Catabasis Pharmaceuticals, Inc. T: (617) 349-1971
amatthews@catabasis.com
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Catabasis Pharmaceuticals (NASDAQ:CATB)
Historical Stock Chart
From Sep 2023 to Sep 2024